Willow Biosciences Inc.
WLLW.TO
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 53.01% | 49.94% | 49.53% | 37.08% | 14.84% |
| Total Depreciation and Amortization | -6.05% | -27.45% | -10.38% | -22.69% | -32.88% |
| Total Amortization of Deferred Charges | -34.85% | -80.92% | -80.92% | -80.92% | -80.92% |
| Total Other Non-Cash Items | -23.20% | -18.77% | -107.34% | -195.32% | 121.40% |
| Change in Net Operating Assets | 439.46% | 220.96% | 228.24% | 104.17% | -249.36% |
| Cash from Operations | 66.42% | 67.86% | 60.26% | 40.02% | 23.35% |
| Capital Expenditure | 96.71% | 79.50% | 84.38% | 92.12% | 17.56% |
| Sale of Property, Plant, and Equipment | 1,862.75% | 78.61% | 14.47% | 14.47% | -94.45% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -100.94% | -118.42% | -88.68% | -45.14% | 201.56% |
| Cash from Investing | -97.76% | 93.70% | -25.20% | 116.08% | 175.17% |
| Total Debt Issued | -133.75% | 610.63% | -- | -- | -- |
| Total Debt Repaid | 15.02% | 22.46% | -29.88% | -44.90% | -39.97% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 4,657.14% | 159.38% | 560.32% | 11,450.00% | -- |
| Cash from Financing | 403.87% | 277.03% | 174.27% | 98.16% | 65.57% |
| Foreign Exchange rate Adjustments | 150.00% | -108.13% | 29.03% | -125.97% | -929.27% |
| Miscellaneous Cash Flow Adjustments | 143.75% | 199.20% | -- | -- | -- |
| Net Change in Cash | 64.73% | 80.96% | 63.21% | 45.23% | 59.91% |